Drug Profile
Escitalopram - Lundbeck A/S
Alternative Names: Cipralex; Entact; Escitalopram Oxalate; Lexapro; LU-26054; MLD-55; S-citalopram; Seroplex; Sipralex; SipralexaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer AbbVie; Forest Laboratories; Lundbeck A/S; Mochida Pharmaceutical
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Benzofurans; Fluorobenzenes; Nitriles; Propylamines; Small molecules
- Mechanism of Action Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia
Most Recent Events
- 22 Nov 2022 Escitalopram is still in phase-III trials for Major depressive disorder (In adolescents, In children) in Japan (PO) (Mochida Pharmaceutical pipeline, November 2022)
- 08 Mar 2022 No development reported - Phase-III for Major depressive disorder (In adolescents, In children) in Japan (PO)
- 08 May 2020 Allergan has been acquired and merged into AbbVie